{"id":"hav-vaccine","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Injection site pain or erythema"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"5–10","effect":"Myalgia"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated hepatitis A virus or viral antigens that trigger both humoral (antibody) and cellular immune responses. This leads to the production of anti-HAV antibodies and immunological memory, preventing infection if exposed to wild-type hepatitis A virus. Protection is typically long-lasting, often lifelong after a complete vaccination series.","oneSentence":"HAV vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:54.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in susceptible populations"},{"name":"Post-exposure prophylaxis for hepatitis A"}]},"trialDetails":[{"nctId":"NCT02772003","phase":"PHASE1","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-06","conditions":"Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07433881","phase":"","title":"Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-25","conditions":"Liver Cirrhosis","enrollment":360},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT04704830","phase":"PHASE3","title":"R21/Matrix-M in African Children Against Clinical Malaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2021-04-29","conditions":"Malaria","enrollment":4800},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":"Genital Warts","enrollment":52},{"nctId":"NCT05770895","phase":"PHASE1","title":"Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-04-03","conditions":"Chronic Hepatitis B","enrollment":83},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT04294433","phase":"PHASE4","title":"Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children","status":"COMPLETED","sponsor":"Laval University","startDate":"2018-06-11","conditions":"Hepatitis B","enrollment":431},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT06576024","phase":"PHASE4","title":"Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People","status":"COMPLETED","sponsor":"LiuZhou People's Hospital","startDate":"2023-12-19","conditions":"Hepatitis A, Immunodeficiency, HIV Infections","enrollment":392},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT04674462","phase":"PHASE4","title":"Understanding Poor Vaccine Responses to Hepatitis B Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-07-07","conditions":"Vaccine Reaction","enrollment":101},{"nctId":"NCT06855836","phase":"NA","title":"Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-03-03","conditions":"Overdose","enrollment":588},{"nctId":"NCT04684914","phase":"PHASE2","title":"HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Altimmune, Inc.","startDate":"2020-12-26","conditions":"Hepatitis B, Chronic","enrollment":87},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT07069569","phase":"PHASE2","title":"A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-05-30","conditions":"Chronic Hepatitis B","enrollment":127},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT04843852","phase":"PHASE1","title":"TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-10-16","conditions":"Hepatitis B, Chronic Hepatitis B","enrollment":10},{"nctId":"NCT00988767","phase":"PHASE1","title":"Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2001-02","conditions":"Chronic Hepatitis B","enrollment":10},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT07185152","phase":"NA","title":"The Effect of Mechanical Vibration and Flick Tapping Methods in Reducing Pain in Infant Vaccination","status":"COMPLETED","sponsor":"Berrin GOGER","startDate":"2024-04-29","conditions":"Health Knowledge, Attitudes, Practice, Health Behavior","enrollment":80},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT03859687","phase":"PHASE1","title":"Trial of Antibody Responses by Vitamin Supplementation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-19","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT07134322","phase":"","title":"From Conflict to Family Trauma","status":"NOT_YET_RECRUITING","sponsor":"University of Bari Aldo Moro","startDate":"2026-02-08","conditions":"Family Conflict, Family Characteristics, Family Dysfunctional","enrollment":200},{"nctId":"NCT07120464","phase":"","title":"Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations","status":"RECRUITING","sponsor":"Liaoning Chengda Biotechnology CO., LTD","startDate":"2025-08-15","conditions":"Rabies Exposure, Immunocompromised, Chronic Disease","enrollment":180},{"nctId":"NCT04297917","phase":"PHASE1","title":"First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-02-10","conditions":"Hepatitis B, Healthy","enrollment":47},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT07051187","phase":"PHASE1","title":"A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Jiyan Liu","startDate":"2025-07-30","conditions":"Chronic Hepatitis B Virus (Hbv)","enrollment":9},{"nctId":"NCT06513286","phase":"PHASE1, PHASE2","title":"TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate","status":"ENROLLING_BY_INVITATION","sponsor":"Michael Hoelscher","startDate":"2025-06-12","conditions":"Chronic Hepatitis B","enrollment":81},{"nctId":"NCT04193189","phase":"PHASE3","title":"B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-14","conditions":"HIV Infection, Hepatitis B","enrollment":638},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT07032610","phase":"","title":"Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents","status":"NOT_YET_RECRUITING","sponsor":"Chiang Mai University","startDate":"2025-06-22","conditions":"Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases","enrollment":60},{"nctId":"NCT06989788","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstriVax Therapeutics","startDate":"2025-05-06","conditions":"Chronic Hepatitis b","enrollment":16},{"nctId":"NCT06978621","phase":"PHASE3","title":"Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV","status":"RECRUITING","sponsor":"Chiang Mai University","startDate":"2025-05-25","conditions":"Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases","enrollment":36},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT05482295","phase":"PHASE3","title":"Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","startDate":"2025-09","conditions":"Vaccine Reaction, Vaccine Adverse Reaction","enrollment":540},{"nctId":"NCT05482282","phase":"PHASE3","title":"Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)","status":"WITHDRAWN","sponsor":"PT Bio Farma","startDate":"2025-12","conditions":"Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction","enrollment":""},{"nctId":"NCT06070051","phase":"PHASE1","title":"Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virion Therapeutics","startDate":"2023-09-26","conditions":"Chronic Hepatitis B","enrollment":56},{"nctId":"NCT03343431","phase":"PHASE3","title":"Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherche pour le Developpement","startDate":"2018-08-02","conditions":"Hepatitis B, Pregnancy","enrollment":504},{"nctId":"NCT05123599","phase":"PHASE1","title":"A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-06","conditions":"Hepatitis B, Chronic","enrollment":24},{"nctId":"NCT02496897","phase":"PHASE1","title":"Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2015-07","conditions":"Hepatitis B","enrollment":61},{"nctId":"NCT03654677","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-09-19","conditions":"Hepatitis A Vaccine","enrollment":253},{"nctId":"NCT06947356","phase":"NA","title":"Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2025-05-03","conditions":"Hepatitis B","enrollment":210},{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT02760537","phase":"NA","title":"Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2013-04","conditions":"Liver Neoplasms, Hepatitis B","enrollment":232},{"nctId":"NCT06306196","phase":"PHASE2","title":"Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-04-04","conditions":"Hepatitis E Virus Infection","enrollment":1040},{"nctId":"NCT05727267","phase":"PHASE1","title":"A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2024-01-23","conditions":"Chronic Hepatitis B","enrollment":24},{"nctId":"NCT05805306","phase":"NA","title":"Entre Herman@s: Promoting Health Among Latino MSM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charles Drew University of Medicine and Science","startDate":"2023-04-29","conditions":"HIV Infections","enrollment":288},{"nctId":"NCT06888479","phase":"PHASE3","title":"Optimal Timing of Hepatitis B Vaccination After Transplants","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-01","conditions":"Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction","enrollment":1500},{"nctId":"NCT04970836","phase":"NA","title":"The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-08-01","conditions":"Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine","enrollment":240},{"nctId":"NCT05272735","phase":"PHASE4","title":"HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2022-12-10","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT01824537","phase":"PHASE4","title":"Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study","status":"COMPLETED","sponsor":"McGill University","startDate":"2014-01","conditions":"Human Papillomavirus Infection","enrollment":372},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06162299","phase":"PHASE1","title":"A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002","status":"TERMINATED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2024-07-01","conditions":"Chronic Hepatitis B","enrollment":16},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT06803368","phase":"NA","title":"Research on Clinical Recovery and Maintenance Strategies for CHB","status":"RECRUITING","sponsor":"Beijing Municipal Administration of Hospitals","startDate":"2024-11-01","conditions":"Chronic Hepatitis b, Hepatitis B Vaccine","enrollment":285},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":"Hepatitis B Vaccine","enrollment":40},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT06454812","phase":"NA","title":"The Effect of Mechanical Vibration and Helfer Skin Tap Technique on Procedural Pain in Infants During Vaccination","status":"COMPLETED","sponsor":"Istanbul Medeniyet University","startDate":"2024-07-15","conditions":"Procedural Pain, Nursing Caries, Pain, Acute","enrollment":108},{"nctId":"NCT02839161","phase":"PHASE1","title":"Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2017-01","conditions":"Hookworm Disease, Hookworm Infection","enrollment":60},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT01926860","phase":"PHASE4","title":"PCV13 + Hepatitis a Vaccine for Adults","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-08-24","conditions":"Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis a","enrollment":305},{"nctId":"NCT06289868","phase":"","title":"Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)","status":"COMPLETED","sponsor":"Beckman Coulter, Inc.","startDate":"2024-02-27","conditions":"HAV","enrollment":1409},{"nctId":"NCT04588077","phase":"PHASE4","title":"Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis","status":"RECRUITING","sponsor":"Mercy Medical Center","startDate":"2020-09-14","conditions":"Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease","enrollment":200},{"nctId":"NCT06690515","phase":"PHASE1, PHASE2","title":"Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","startDate":"2025-03-01","conditions":"Vaccine Adverse Reaction, Vaccine Reaction","enrollment":465},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT06377748","phase":"NA","title":"The Effect of Facilitated-tucking and ShotBlocker on Pain Caused by Vaccination in Healthy Infants","status":"COMPLETED","sponsor":"Istanbul Medeniyet University","startDate":"2024-06-15","conditions":"Procedural Pain, Pain, Acute, Nursing Caries","enrollment":142},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT02917577","phase":"NA","title":"Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2016-11-22","conditions":"Autoimmune Rheumatologic Disease","enrollment":19},{"nctId":"NCT05808166","phase":"PHASE2","title":"Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-05-02","conditions":"Hepatitis E Infection","enrollment":2358},{"nctId":"NCT02374450","phase":"","title":"A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Malaria","enrollment":36366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":260,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HAV vaccine","genericName":"HAV vaccine","companyName":"International Agency for Research on Cancer","companyId":"international-agency-for-research-on-cancer","modality":"Biologic","firstApprovalDate":"","aiSummary":"HAV vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A infection in susceptible populations, Post-exposure prophylaxis for hepatitis A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}